[Usefulness of neuron specific enolase in patients with head and neck malignant tumors].
The authors present results of evaluation of neuron specific enolase (NSE) in 146 persons. We analyzed a concentration of NSE in preliminary study and in monitoring depending on clinical advances of tumour, mass of primary tumour and metastases to lymph nodes. Neuron specific enolase was excluded because the number of positive results was the same both in the main and control group. Our results indicate that evaluation of NSE have not height value in monitoring patients with head and neck carcinoma.
Adamiak
Grzegorz
G
Klinika Otolaryngologiczna Centralnego Szpitala Klinicznego Wojskowej Akademii Medycznej w Warszawie.
Ligeziński
Aleksander
A
Jurkiewicz
Dariusz
D
Hermanowski
Maciej
M
Konieczna
Maria
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D002294:Carcinoma, Squamous Cell / Q000201:enzymology* / Q000473:pathology / Q000556:secondary*; D005260:Female; D006258:Head and Neck Neoplasms / Q000201:enzymology* / Q000473:pathology; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010751:Phosphopyruvate Hydratase / Q000378:metabolism*
D014408:Biomarkers, Tumor; D010751:Phosphopyruvate Hydratase
Przydatność oznaczeń neuronowej swoistej enolazy u chorych na nowotwory złośliwe głowy i szyi.